mage-a1特异性tcr及tcr-t因此有希望成为具有高抗肿瘤疗效和低脱靶效应的癌症疗法。 技术实现思路 0、发明概述 1、根据本发明的第一方面,提供一种分离的特异性结合主要组织兼容性复合体(mhc)/mage-a1表位复合体的肿瘤特异性t细胞受体(tcr)或其抗原结合结构域,所述肿瘤特异性tcr包括:tcrα链,所述tcrα链包含具有se...
其中涉及细胞毒性T细胞、辅助T细胞及功能上不同的效应T细胞和记忆T细胞。细胞毒性T细 胞可以通过其表面的T细胞受体(TCR)特异性结合并识别表达肿瘤抗原的癌细胞,并通过释 放细胞因子、酶和细胞毒素或者通过经由细胞‑细胞相互作用引发促凋亡信号级联反应来 杀灭癌细胞。 [0003]过继淋巴细胞疗法(ACT)通过对受试者施用...
The present invention relates to an isolated T cell receptor (TCR) specific for a MAGEA1- derived peptide and to a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a ...
Additionally, the use of CorreGene's SMART-TCR system has facilitated the acquisition of TCRs with high affinities in the pico-molar range. By leveraging CR62 and a high-affinity TCR, we have conceptualized the TCR-based T-cell engager, CRPA1A2. Comprehensive preclinical assessments have been...
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother 2013;62:773–785. 43 van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science...
Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells... - 《Science Translational Medicine》 被引量: 0发表: 2013年 Cardiovascular Toxicity and Titin Cross-Reactivity of Affinity-Enhanced TCR-Engineered T Cells Against HLA-...
MAGE‑A1特异性TCR及TCR‑T因此有希望成为具有高抗肿瘤疗效和低脱靶效应的癌症疗法。 [0006]发明概述 [0007]根据本发明的第一方面,提供一种分离的特异性结合主要组织兼容性复合体(MHC)/MAGE‑A1表位复合体的肿瘤特异性T细胞受体(TCR)或其抗原结合结构域,所述肿瘤特异性TCR包括:TCRα链,所述TCRα链包含具有...
MAGE‑A1特异性TCR及TCR‑T因此有希望成为具有高抗肿瘤疗效和低脱靶效应的癌症疗法。发明内容 [0006]根据本发明的第一方面,提供一种分离的特异性结合主要组织兼容性复合体(MHC)/MAGE‑A1表位复合体的肿瘤特异性T细胞受体(TCR)或其抗原结合结构域, 所述肿瘤特异性TCR包括: TCRα链, 所述TCRα链包含具有SEQ ...
Additionally, the use of CorreGene's SMART-TCR system has facilitated the acquisition of TCRs with high affinities in the pico-molar range. By leveraging CR62 and a high-affinity TCR, we have conceptualized the TCR-based T-cell engager, CRPA1A2. Comprehensive preclinical assessments have been...
The present invention relates to the field of immunotherapy, in particular, adoptive T cell therapy of MAGEA1-associated cancer. TCR alpha chain constructs (TRA) and/or a TCR beta chain constructs (TRB) of TCR constructs specific for an epitope in complex with a human MHC-I, wherein the ...